The prognostic value of sarcopenia combined with preoperative fibrinogen–albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study

Haitao Yu1,2 | Mingxun Wang1,2 | Yi Wang3 | Jinhuan Yang1,2 | Liming Deng1,2 | Wenming Bao1,2 | Bangjie He1,2 | Zixia Lin1,2 | Ziyan Chen1,2 | Kaiyu Chen1,2 | Baofu Zhang1,2 | Fangting Liu1,2 | Zhengping Yu1,2 | Longyun Ye1,2 | Bin Jin4 | Gang Chen1,2

1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
3Department of Epidemiology and Biostatistics, School of Public Health and Management, Wenzhou Medical University, Wenzhou, China
4Department of Liver Transplantation, Qilu Hospital of Shandong University, Jinan, China

*Correspondence
Gang Chen, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Fuxue Road, Wenzhou, Zhejiang 325035, China. Email: chen.gang@wmu.edu.cn
Bin Jin, Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Wenhua Road, Jinan, Shandong 250012, China. Email: jinbin9449@126.com

Abstract

Background: To explore the prognostic value of the fibrinogen–albumin ratio (FAR) combined with sarcopenia in intrahepatic cholangiocarcinoma (ICC) patients after surgery and to develop a nomogram for predicting the survival of ICC patients.

Materials and Methods: In this prospective cohort study, 116 ICC patients who underwent radical surgery were enrolled as the discovery cohort and another independent cohort of 68 ICC patients was used as the validation cohort. Kaplan–Meier method was used to analyze prognosis. The independent predictor of overall survival (OS) and recurrence-free survival (RFS) was evaluated by univariable and multivariable Cox regression analyses, then developing nomograms. The performance of nomograms was evaluated by concordance index (C-index), calibration curve, receiver operating characteristic curve analysis (ROC), and decision curve analysis (DCA).

Results: Patients with high FAR had lower OS and RFS. FAR and sarcopenia were effective predictors of OS and RFS. Patients with high FAR and sarcopenia had a poorer prognosis than other patients. OS nomogram was constructed based on age, FAR, and sarcopenia. RFS nomogram was constructed based on FAR and sarcopenia. C-index for the nomograms of OS and RFS was 0.713 and 0.686. Calibration curves revealed great consistency between actual survival and nomogram prediction. The area under ROC curve (AUC) for the nomograms of OS and RFS was 0.796 and 0.791 in the discovery cohort, 0.823 and 0.726 in the validation cohort. The clinical value of nomograms was confirmed by the DCA.
INTRODUCTION

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor in the liver after hepatocellular carcinoma. In the past two decades, the incidence of ICC has risen worldwide, however, the prognosis of ICC patients is worse than other cancers, and the 5-year survival rate after diagnosis is below 10%. Radical surgery and liver transplantation are the only effective treatments for ICC, but only about 35% of patients are eligible for these treatments. At present, the 5-year overall survival of ICC patients after radical resection is 25%–40%. The factors affecting the prognosis of ICC patients who accepted radical surgery are still unclear, hence, it is particularly significant to find non-invasive and convenient factors that affect the prognosis of patients with ICC, and according to these indicators to establish an effective treatment strategy after surgery.

The survival time of patients with malignant tumor is associated with many factors, such as systemic inflammation indicators and nutritional status. For cancer patients, malnutrition is a serious problem, it will directly lead to cachexia, worse treatment effect, and shorter survival time. At the same time, circulating inflammatory markers that mediate systemic inflammatory response play a vital role in the occurrence and development of many cancers. They destroy human immunity, reduce tumor response to cytotoxic drugs, and ultimately shorten the survival time of patients with ICC. Albumin and fibrinogen are the two most common biomarkers of inflammation. Recent studies reported that albumin was associated with the prognosis of many diseases, such as Oral Cavity cancer, metastatic pathological femur fractures, and amyotrophic lateral sclerosis. Besides, previous studies showed that fibrinogen has the function of predicting the prognosis of diseases, such as spontaneous cerebral hemorrhage and renal cancer. More and more studies have shown that high fibrinogen and low albumin are correlated with poor prognosis in cancer patients. As a new prognostic immune biomarker, the fibrinogen–albumin ratio (FAR) has more prognostic value than high fibrinogen or low serum albumin. In fact, FAR has been reported as a potential prognostic factor for many malignant tumors, such as gallbladder cancer, breast cancer, colorectal cancer, and pancreatic cancer. However, the relationship between FAR and the prognosis of patients with ICC has not yet been explored.

Sarcopenia is a disease characterized by a decline in body muscle mass and loss of function. The loss of muscle mass is one of the three major phenotypes of malnutrition. Recent studies suggested that sarcopenia was associated with the poor prognosis of many malignant tumors, such as esophageal cancer, colorectal cancer, and hepatocellular carcinoma. Sarcopenia and inflammation marker FAR are usually used alone as prognostic factors instead of building a combined model to predict the prognosis of cancer patients.

Recently, we had also proved the prognostic value of sarcopenia in ICC patients, and sarcopenia combined with hepatolithiasis may have better predictive potential. In this study, our purpose was to explore the relationship between the inflammatory biomarker FAR and the prognosis of ICC patients, and to explore whether sarcopenia combined with FAR can accurately predict the prognosis of ICC patients after radical resection. Moreover, we had developed and verified the nomograms based on these two factors to accurately predict the OS and RFS of ICC patients who accepted the radical surgery.

MATERIALS AND METHODS

2.1 Patients

A total of 234 ICC patients who underwent surgery were recruited for the discovery cohort and validation cohort during the study period in two centers. The consecutive recruitment of the discovery cohort of this study started in August 2012, after the selection of exclusion criteria, 116 patients who underwent radical surgery at the First Affiliated Hospital of Wenzhou Medical University from January 2013 to October 2017.
2019 were finally included in the discovery cohort. From August 2015 to October 2019, an independent validation cohort of 68 patients was screened from Qilu Hospital of Shandong University using the same criteria as that for the discovery cohort. The inclusion criteria of ICC patients were as follows: (a) histologically confirmed as primary intrahepatic cholangiocarcinoma with R0 radical resection; (b) no anti-tumor therapy such as chemotherapy and radiotherapy before radical resection; (c) no uncontrollable acute infection, chronic renal failure, hematopoietic system disease or other malignant tumors; (d) complete clinical data available at the time of the first diagnosis, including hematological indicators and plain CT image to analyze psoas muscle index (PMI). The exclusion criteria of ICC patients in this study were: (a) pathologically confirmed not to be primary ICC or combined with hepatocellular carcinoma; (b) perioperative death; (c) underwent palliative surgery or R1/R2 resection; (d) received preoperative antitumor therapy; (e) loss of follow-up; (f) missing value in clinical data including lymph node metastasis, CT image data, and hematological indicators.

2.2 | Preoperative anthropometric and image analysis

Physical status and laboratory indicators are obtained within 2 weeks before surgery. BMI is calculated by dividing weight (kg) by the square of height (m²). We use the total psoas muscle mass areas (PMS) as an index to judge the patient’s muscle mass in this study. 26–28 PMI is used as a simple indicator to define sarcopenia, the calculation formula of PMI is as follows:

$$\text{PMI} = \frac{\text{total psoas muscle mass areas (cm}^2\text{) / height}^2 \text{(m}^2\text{)}}{1}.$$  

We analyzed the plain CT image at the level of the third lumbar vertebra to calculate the PMS, PMS was calculated as follows:

![Diagram](image_url)

**FIGURE 1** The flow diagram of the patients with discovery and validation cohorts (A). Kaplan-Meier curves of OS (B) and RFS (C) stratified according to FAR in the discovery cohort. Abbreviations: FAR, fibrinogen-albumin ratio; OS, overall survival; RFS, recurrence-free survival
| Variables                      | FAR ≤ 0.0875 (n = 38) | FAR > 0.0875 (n = 78) | Total (n = 116) | p value |
|-------------------------------|-----------------------|-----------------------|-----------------|---------|
| Age (year), n, %              |                       |                       |                 |         |
| <65                           | 24                    | 63.2%                 | 36              | 46.2%   | 60 |
| ≥65                           | 14                    | 36.8%                 | 42              | 53.8%   | 56 |
| Gender, n, %                  |                       |                       |                 |         | 0.475 |
| Male                          | 19                    | 50%                   | 32              | 41.0%   | 51 |
| Female                        | 19                    | 50%                   | 46              | 59.0%   | 65 |
| TNM stage, n, %               |                       |                       |                 |         | 0.117 |
| I-II                          | 33                    | 86.8%                 | 56              | 71.8%   | 89 |
| III-IV                        | 5                     | 13.2%                 | 22              | 28.2%   | 27 |
| Tumor differentiation, n, %   |                       |                       |                 |         | 0.004 |
| Low                           | 5                     | 13.2%                 | 25              | 32.1%   | 30 |
| High                          | 33                    | 86.8%                 | 53              | 67.9%   | 86 |
| Tumor size (cm), n, %         |                       |                       |                 |         | 0.131 |
| <5                            | 22                    | 57.9%                 | 32              | 41.0%   | 54 |
| ≥5                            | 16                    | 42.1%                 | 46              | 59.0%   | 62 |
| Tumor number, n, %            |                       |                       |                 |         | 0.057 |
| Single                        | 31                    | 81.6%                 | 73              | 93.6%   | 104 |
| Multiple                      | 7                     | 18.4%                 | 5               | 6.4%    | 12 |
| HBsAg, n, %                   |                       |                       |                 |         | 0.475 |
| Negative                      | 21                    | 55.3%                 | 50              | 64.1%   | 71 |
| Positive                      | 17                    | 44.7%                 | 28              | 35.9%   | 45 |
| Lymph node invasion, n, %     |                       |                       |                 |         | 0.283 |
| No                            | 34                    | 89.5%                 | 62              | 79.5%   | 96 |
| Yes                           | 4                     | 10.5%                 | 16              | 20.5%   | 20 |
| Vascular invasion, n, %       |                       |                       |                 |         | 0.756 |
| No                            | 30                    | 78.9%                 | 58              | 74.4%   | 88 |
| Yes                           | 8                     | 21.1%                 | 20              | 25.6%   | 28 |
| Perineural invasion, n, %     |                       |                       |                 |         | 0.196 |
| No                            | 33                    | 86.8%                 | 58              | 74.4%   | 91 |
| Yes                           | 5                     | 13.2%                 | 20              | 25.6%   | 25 |
| Smoking history, n, %         |                       |                       |                 |         | 1     |
| No                            | 28                    | 73.7%                 | 57              | 73.1%   | 85 |
| Yes                           | 10                    | 26.3%                 | 21              | 26.9%   | 31 |
| Drinking history, n, %        |                       |                       |                 |         | 1     |
| No                            | 28                    | 73.7%                 | 59              | 75.6%   | 87 |
| Yes                           | 10                    | 26.3%                 | 19              | 24.4%   | 29 |
| Liver cirrhosis, n, %         |                       |                       |                 |         | 1     |
| No                            | 30                    | 78.9%                 | 61              | 78.2%   | 91 |
| Yes                           | 8                     | 21.1%                 | 17              | 21.8%   | 25 |
| Portal hypertension, n, %     |                       |                       |                 |         | 0.102 |
| No                            | 35                    | 92.1%                 | 77              | 98.7%   | 112 |
| Yes                           | 3                     | 7.9%                  | 1               | 1.3%    | 4  |
| Child–Pugh grade, n, %        |                       |                       |                 |         | 0.139 |
| A                             | 36                    | 94.7%                 | 65              | 83.3%   | 101 |
| B                             | 2                     | 5.3%                  | 13              | 16.7%   | 15  |
| BMI (Kg/m²), n, %             |                       |                       |                 |         | 0.265 |
| ≤22.66                        | 17                    | 44.7%                 | 45              | 57.7%   | 62  |

(Continues)
where a and b are the radii of the major and minor axes, respectively. All preoperative plain CT imaging was obtained within 1 month before surgery and the CT images were analyzed by two physicians separately.

### 2.3 Data collection

The clinicopathological information of each patient is obtained from the medical records, including: age, gender, TNM stage, tumor differentiation, tumor size, tumor number, HBsAg, lymph node invasion, vascular invasion, BMI, AFP, CEA, CA19-9, smoking history, drinking history, liver cirrhosis, perineural invasion, portal hypertension, Child-Pugh grade, serum albumin, FAR, and PMI. TNM stage is according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for ICC. Lymph node invasion, vascular invasion, perineural invasion, and liver cirrhosis were detected by the pathology of postoperative specimens. The discovery outcomes in this study were OS and RFS. OS was defined as the period from the day of surgery to death or the last follow-up, RFS was defined as the period between the date of surgical resection and date of ICC relapse or death. The deadline for follow-up was 20th May 2020.

### 2.4 Ethics statement

This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and Qilu Hospital of Shandong University. All patients signed written informed consent.

### 2.5 Statistical analysis

Normally distributed data were showed as mean±standard deviation and non-normally distributed data were reported as medians and interquartile range. Categorical variables were presented in the form of frequencies and percentages. Comparisons of baseline characteristics between groups were tested by Pearson’s chi-square test or Fisher’s exact test. The cut-off values of FAR and PMI for OS and RFS were calculated by X-tile software. The K–M method was carried out to analyze the OS and RFS of ICC patients. The predictive factors for OS and RFS were evaluated by univariate and multivariate Cox regression analyses. The clinically significant factors calculated from the multivariate analysis were integrated into nomograms to predict the prognosis of ICC patients who underwent radical surgery. The performance of nomograms was evaluated by the C-index and Calibration plots. The DCA and ROC were used to assess the predictive accuracy and net benefit of the nomograms.

### TABLE 1 (Continued)

| Variables               | FAR ≤ 0.0875 (n = 38) | FAR > 0.0875 (n = 78) | Total (n = 116) | p value |
|-------------------------|-----------------------|-----------------------|-----------------|---------|
| >22.66                  | 21 55.3%              | 33 42.3%              | 54              |         |
| AFP (µg/L), n, %        |                       |                       |                 |         |
| ≤9                      | 33 86.8%              | 76 97.4%              | 109             | 0.037   |
| >9                      | 5 13.2%               | 2 2.6%                | 7               |         |
| CEA (µ/L), n, %         |                       |                       |                 | 0.187   |
| ≤5                      | 31 81.6%              | 53 67.9%              | 84              |         |
| >5                      | 7 18.4%               | 25 32.1%              | 32              |         |
| CA19-9 (µ/ml), n, %     |                       |                       |                 | 0.002   |
| ≤37                     | 22 57.9%              | 21 26.9%              | 43              |         |
| >37                     | 16 42.1%              | 57 73.1%              | 73              |         |
| Serum albumin (g/L), n, % |                     |                       |                 | <0.001  |
| ≤35                     | 1 2.6%                | 25 32.1%              | 26              |         |
| >35                     | 37 97.4%              | 53 67.9%              | 90              |         |
| Fibrinogen              |                       |                       |                 | 0.032   |
| ≤4                      | 1 2.6%                | 15 19.2%              | 16              |         |
| >4                      | 37 97.4%              | 63 87.8%              | 100             |         |
| PMI, n, %               |                       |                       |                 | 0.825   |
| Low                     | 15 39.5%              | 34 43.6%              | 49              |         |
| High                    | 23 60.5%              | 44 56.4%              | 67              |         |

Abbreviations: AFP, alpha-fetoprotein; BMI, body mass index; CA19-9, Carbohydrate antigen199; CEA, carcinoembryonic antigen; FAR, fibrinogen-albumin ratio; PMI, psoas muscle index.

\[
PMS = a \times b \times \pi,
\]

where a and b are the radii of the major and minor axes, respectively. All preoperative plain CT imaging was obtained within 1 month before surgery and the CT images were analyzed by two physicians separately.
analysis was performed using R, version 3.5.2 (R packages "rms," "survival," "survminer," "timeROC," "forestplot," "stdca"). A p < 0.05 was considered to be statistically significant.

### RESULTS

#### 3.1 FAR as a potential prognostic factor of ICC

A total of 153 ICC patients who underwent surgery were recruited for the discovery cohort. After the exclusion criteria, 116 patients were finally enrolled in the discovery cohort (Figure 1A), based on the optimal cut-off value calculated by x-tile, the patients were divided into high-risk group (FAR > 0.0875, n = 78, 67.2%) and low-risk group (FAR ≤ 0.0875, n = 38, 32.8%). The relationship between clinicopathological factors and FAR in the discovery cohort is listed in Table 1. Patients with high FAR had a poorer tumor differentiation (p = 0.004), higher CA19-9 (p = 0.002), and lower AFP (p = 0.037) compared to those in the low FAR group. The K–M analysis showed that the patients in the high-risk group had shorter OS and RFS than those in the low-risk group (p < 0.001 in Figure 1B p < 0.001 in Figure 1C, respectively). According to univariate and multivariate Cox proportional regression analyses, FAR was an independent risk factor for OS and RFS in patients with ICC (HR: 2.00, 95% CI: 1.04–3.85, p = 0.038 in Figure 2C, HR: 2.07, 95% CI: 1.07–4.02, p = 0.03 in Figure 2D, respectively).

#### 3.2 Prognosis of patients and baseline characteristics

For the discovery cohort, the average age of the patient was 64.94 ± 10.12 years, 51 (44%) patients were men and 65 (56%) were women. Most patients were classified as AJCC8th I and II stage (76.7%), there were 86 (74.1%) patients whose tumor differentiation is well-differentiated. Tumor size in 54 (46.6%) patients was less than 5 cm and 104 (89.7%) patients had a single tumor. The median PMI for men was 8.86 cm²/m² (IQR, 7.31–11.11) and 6.43 cm²/m² (IQR, 5.35–8.39). Sex-specific cut-off values of PMI were calculated in the discovery cohort using discrete Cox regression analyses with death time as the outcome.

![FIGURE 2](image)

**FIGURE 2** Univariate and multivariate Cox regression analysis for OS and RFS. univariate Cox regression analyses for determining the potential prognostic factors for OS (A) and RFS (B) in discovery cohort, multivariate Cox regression analyses for determining the independent potential prognostic factors for OS (C) and RFS (D) in discovery cohort. Abbreviations: AFP, alpha-fetoprotein; BMI, body mass index; CA19-9, Carbohydrate antigen199; CEA, carcinoembryonic antigen; FAR, fibrinogen-albumin ratio; OS, overall survival; PMI, psoas muscle index; RFS, recurrence-free survival.
X-tile software, men’s PMI cut-off value was 8.6 cm\(^2\)/m\(^2\), for women was 6.0 cm\(^2\)/m\(^2\), we defined a PMI below 8.6 cm\(^2\)/m\(^2\) in men and 6.0 cm\(^2\)/m\(^2\) in women as sarcopenia. The baseline characteristics of the discovery and validation cohorts are presented in Table 2. The median follow-up time was 33.9 months (1.05–79.64 months) and the median OS was 11.80 months, the OS probabilities at 1 year, 3 years, and 5 years were 66.4%, 30.0%, and 19.0%, respectively. The median RFS was 8.01 months, the RFS probabilities at 1 year, 3 years, and 5 years were 45.8%, 21.7%, and 16.7%, respectively. A total of 68 ICC

| Variables                        | Discovery cohort (n = 116) | Validation cohort (n = 68) | Total (n = 184) | p value |
|----------------------------------|---------------------------|---------------------------|-----------------|---------|
| Age (year), n, %                 |                           |                           |                 | 0.695   |
| <65                              | 60                        | 38                        | 98              |         |
| ≥65                              | 56                        | 30                        | 86              |         |
| Gender, n, %                     |                           |                           |                 | 0.073   |
| Male                             | 51                        | 40                        | 91              |         |
| Female                           | 65                        | 28                        | 93              |         |
| TNM stage, n, %                  |                           |                           |                 | 0.017   |
| I-II                             | 89                        | 40                        | 129             |         |
| III-IV                           | 27                        | 28                        | 55              |         |
| Tumor differentiation, n, %      |                           |                           |                 | 0.003   |
| Low                              | 30                        | 33                        | 63              |         |
| High                             | 86                        | 35                        | 121             |         |
| Tumor size (cm), n, %            |                           |                           |                 | 0.053   |
| <5                               | 54                        | 21                        | 75              |         |
| ≥5                               | 62                        | 47                        | 109             |         |
| Tumor number, n, %               |                           |                           |                 | 1       |
| Single                           | 104                       | 61                        | 165             |         |
| Multiple                         | 12                        | 7                         | 19              |         |
| HBsAg, n, %                      |                           |                           |                 | 0.009   |
| Negative                         | 71                        | 55                        | 126             |         |
| Positive                         | 45                        | 13                        | 58              |         |
| Lymph node invasion, n, %        |                           |                           |                 | 0.904   |
| No                               | 96                        | 55                        | 151             |         |
| Yes                              | 20                        | 13                        | 33              |         |
| Vascular invasion, n, %          |                           |                           |                 | 0.112   |
| No                               | 88                        | 59                        | 147             |         |
| Yes                              | 28                        | 9                         | 37              |         |
| Perineural invasion, n, %        |                           |                           |                 | 0.343   |
| No                               | 91                        | 58                        | 149             |         |
| Yes                              | 25                        | 10                        | 35              |         |
| Smoking history, n, %            |                           |                           |                 | 0.039   |
| No                               | 85                        | 39                        | 124             |         |
| Yes                              | 31                        | 29                        | 60              |         |
| Drinking history, n, %           |                           |                           |                 | 0.012   |
| No                               | 87                        | 38                        | 125             |         |
| Yes                              | 29                        | 30                        | 59              |         |
| Liver cirrhosis, n, %            |                           |                           |                 | 0.487   |
| No                               | 91                        | 57                        | 148             |         |

(Continues)
patients were enrolled in the validation cohort, of those, the median follow-up time was 20.7 months (2.04–52.51 months) and the median OS was 13.21 months, the estimated OS rate at 1 year and 3 years was 68.5% and 36.4%. The median RFS was 11.76 months, and the estimated RFS rate at 1 year and 3 years was 63.0% and 36.4%, respectively.

### 3.3 Independent risk factors for OS and RFS in the discovery cohort

To determine the potential independent risk factors for OS and RFS in the discovery cohort, univariate and multivariate Cox proportional regression analyses were performed. As shown in Figure 2, age, TNM stage, tumor differentiation, BMI, CEA, CA19-9, FAR, and PMI were risk factors related to both OS and RFS in univariate analysis. These eight factors were enrolled in the multivariate model, the result of multivariate analysis suggested that age (HR: 1.68, 95% CI: 1.00–2.80, \( p = 0.049 \)), FAR (HR: 2.00, 95% CI: 1.04–3.85, \( p = 0.038 \)), and PMI (HR: 0.35, 95% CI: 0.21–0.59, \( p < 0.001 \)) were significant independent risk factors for OS. FAR (HR: 2.07, 95% CI: 1.07–4.02, \( p = 0.03 \)) and PMI (HR: 0.41, 95% CI: 0.24–0.68, \( p < 0.001 \)) were also significant independent risk factors for RFS in multivariate analysis.

### 3.4 The prognostic value of FAR combine with sarcopenia in ICC patients

According to the level of FAR and sarcopenia, we divided the patients in the discovery cohort into four groups,
sarcopenia with high FAR (S-HF), sarcopenia with low FAR (S-LF), non-sarcopenia with high FAR (NS-HF), and non-sarcopenia with low FAR (NS-LF). The survival curve showed the median OS of the S-HF group was 10.8 months, S-LF group was 20.7 months, NS-HF group was 24.2 months, and NS-LF group was 51.2 months. Furthermore, the survival of S-HF and NS-LF (p < 0.001), and S-HF and NS-HF (p = 0.002) had a significant difference. However, there was no significant difference between S-HF and S-LF (p = 0.067 Figure 3A). Moreover, the median RFS of group S-HF, S-LF, NS-HF were 6.6 months, 16.6 months, and 12.3 months, respectively. Obvious differences were observed between S-HF and NS-LF (p < 0.001), S-HF and NS-HF (p = 0.005), and S-HF and S-LF (p = 0.041 Figure 3B).

### 3.5 Development and verification of the OS and RFS nomograms

Based on the independent risk factors in the multivariate analysis, two nomograms were constructed to predict the OS and RFS of ICC patients (Figure 3C and 3D). The C-index of two nomogram models reached 0.713 and 0.686 in the discovery cohort. The calibration curves showed good consistency between the nomogram prediction and actual survival for 3-year OS and RFS in the discovery cohort (Figure 4A and 4B) and validation cohort (Figure 4C and 4D). In addition, the ROC curves demonstrated good discrimination to predict the 3-year OS and RFS in the discovery cohort, the AUC was 0.796 and 0.791 (Figure 4E and 4F). Similarly, high AUC was also noticed for the validation cohort, the AUC of OS and RFS were 0.823 and 0.726, respectively (Figure 4G and 4H). The DCA curves revealed that compared with PMI and FAR, the combined model had better net benefits both in the discovery cohort (Figure 4I and 4J) and validation cohort (Figure 4K and 4L). In order to evaluate the discriminatory of these two nomograms, the patients in the discovery and the verification cohort were divided into the high-risk group and low-risk group based on the risk scores calculated by each nomogram. The K–M analysis revealed that patients in the high-risk group had shorter OS and RFS than patients in the low-risk group (Figure 5).

### 4 DISCUSSION

Increasing evidence showed that systemic inflammatory response and malnutrition were important factors affecting the prognosis of ICC patients after surgery. As a new
HAITAOYU et al. indicator of inflammation, FAR was related to the prognosis of many malignant tumors, but its role in ICC was not yet clear. Sarcopenia usually represented malnutrition in patients because of the decline of skeletal muscle mass. This study demonstrated that the FAR was an independent risk factor for the prognosis of ICC patients after surgery and combined with sarcopenia to construct a prognostic nomogram model. After various methods of verification, the nomogram models we built showed satisfactory prediction performance.

Recently, Systemic inflammation was widely recognized to participate in tumorigenesis and cancer progression, by facilitating tumor angiogenesis, stimulating the proliferation of cancer cells, and accelerating tissue infiltration. Various inflammatory biomarkers can effectively represent the systemic inflammatory response, so they were often used to predict the prognosis of cancer patients. In past reports, a large number of inflammatory indicators had been reported to have close relation to the prognosis of patients with intrahepatic cholangiocarcinoma, including platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), C-reactive protein (CRP), and Glasgow Prognostic Score (GPS). Recently, another inflammation biomarker FAR was found to be associated with the prognosis of many cancers. To our best knowledge, this was the first study to prove that FAR was of great significance in predicting the prognosis of ICC. Moreover, FAR would be a valuable biomarker for predicting the prognosis of ICC, because it can be easily obtained from peripheral blood examinations.

In our study, PMI is considered as a symbol to define sarcopenia, because it is relatively easy to obtain and studies have proven that it is feasible. Thus far, no standard reference value for PMI has been determined. In our study, optimal cut-off values for PMI were calculated by X-tile software in the discovery cohort, the result showed that PMI cut-off
value in men was 8.6 cm²/m², for women was 6.0 cm²/m², which was different from the result of Hahn’s study among the Germans (5.7 cm²/m² in men, 5.1 cm²/m² in women) and Chakedis’s study among the Americans (7.9 cm²/m² in men, 6.5 cm²/m² in women). These differences may be caused by different stratification methods and different ethnic groups. Okumura et al. confirmed that sarcopenia had a close relation to the survival of ICC patients with TNM stage I-III. We also proved that sarcopenia was a potential prognostic factor in ICC patients after surgery, which was in line with previous reports. In past studies, either FAR or sarcopenia was often used as a single predictor rather than a combined indicator. We are the first to combine FAR with sarcopenia to predict the prognosis of ICC patients undergoing radical surgery, and the results show that patients with sarcopenia and high FAR have significantly shorter survival time than other patients. These results are consistent with our clinical experience, patients with preoperative high inflammation and preoperative low nutrition have poorer outcomes. In order to test the reliability and practicability of this conclusion, we established the nomograms for OS and RFS then carried out external verification, the results of external verification were satisfactory.

There are some limitations to this study. First, this study only included patients with ICC who underwent radical surgery. The nomograms we established may not be suitable for patients with ICC who received other treatments, such as palliative surgery and chemotherapy. Second, this study has internal verification and external verification, however, the patients included in our study are from China, future studies are needed to verify this conclusion in different races and regions. Third, in addition to the factors that associated with the prognosis of patients discussed in this study, there were many factors not included in this study, such as resection margin, involvement of extrahepatic margin, type of tumor (mass forming, periductal infiltrating type, intraductal growth

**FIGURE 5** Kaplan-Meier curves of risk stratification for ICC patients. The Kaplan-Meier curves of OS (A) and RFS (B) for risk stratification according to nomogram score in discovery cohort, and OS (C) and RFS (D) in validation cohort. Abbreviations: ICC, intrahepatic cholangiocarcinoma; OS, overall survival; RFS, recurrence-free survival.
5 | CONCLUSIONS

In conclusion, high levels of FAR and sarcopenia are related to the poor prognosis of ICC patients, which are independent risk factors for OS and RFS in ICC patients undergoing radical surgery. FAR and sarcopenia are convenient, inexpensive, and reliable marks that provide references for improving the prognosis and new treatment strategies for ICC patients after surgery.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

ETHICS STATEMENT

This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and Qilu Hospital of Shandong University. All patients signed written informed consent.

DATA AVAILABILITY STATEMENT

The data, models, and code generated or used during the study are available from the corresponding author by reasonable request.

ORCID

Bin Jin https://orcid.org/0000-0002-1411-2631

Gang Chen https://orcid.org/0000-0002-9611-8593

REFERENCE

1. Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848-854. https://doi.org/10.1016/j.jhep.2011.11.015.

2. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19-31. https://doi.org/10.1111/liv.14095.

3. Rizvi S, Khan SA, Hallemeyer CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95-111. https://doi.org/10.1038/nrclinonc.2017.157.

4. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280. https://doi.org/10.1038/nrgastro.2016.51.

5. Mazzasferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364-377. https://doi.org/10.1016/j.jhep.2019.11.020.

6. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. https://doi.org/10.1186/1475-2891-9-69.

7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. https://doi.org/10.1038/nature07205.

8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013.

9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. https://doi.org/10.1038/nature01322.

10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545. https://doi.org/10.1016/S0140-6736(00)04046-0.

11. Valero C, Zanoni DK, Pillai A, et al. Host factors independently associated with prognosis in patients with oral cavity cancer. JAMA Otolaryngol Head Neck Surg. 2020;146(8):699. https://doi.org/10.1001/jamaoto.2020.1019.

12. Sim DS, Zainul-Abidin S, Sim EY, et al. Serum albumin level predicts survival after surgical treatment of metastatic femur fractures: a retrospective study. J Orthop Surg Res. 2020;15(1):128. https://doi.org/10.1186/s13018-020-01632-7.

13. Sun J, Carrero JJ, Zagai U, et al. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(11):2125-2133. https://doi.org/10.1111/ene.14409.

14. Song X, Zhang Q, Cao Y, Wang S, Zhao J. Antiplatelet therapy does not increase mortality of surgical treatment for spontaneous intracerebral haemorrhage. Clin Neurol Neurosurg. 2020;196:105873. https://doi.org/10.1016/j.clineuro.2020.105873.

15. Bian Z, Meng J, Niu Q, et al. Prognostic role of prothrombin time activity, prothrombin time, albumin/globulin ratio, platelets, sex, and fibrinogen in predicting recurrence-free survival time of renal cancer. Cancer Manag Res. 2020;12:8481-8490. https://doi.org/10.2147/cmar.s264856.

16. Xu WY, Zhang HH, Xiong JP, et al. Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. World J Gastroenterol. 2018;24(29):3281-3292. https://doi.org/10.3748/wjg.v24.i29.3281.

17. Hwang KT, Chung JK, Roh EY, et al. Prognostic influence of preoperative fibrinogen to albumin ratio for breast cancer. J Breast Cancer. 2017;20(3):254-263. https://doi.org/10.4048/jbc.2017.20.3.254.

18. Zhang L, Zhang J, Wang Y, et al. Potential prognostic factors for predicting the chemotherapeutic outcomes and prognosis of patients with metastatic colorectal cancer. J Clin Lab Anal. 2019;33(8):e22958. https://doi.org/10.1002/jcla.22958.

19. Fang L, Yan FH, Liu C, et al. Systemic inflammatory biomarkers, especially fibrinogen to albumin ratio, predict prognosis in patients with pancreatic cancer. Cancer Res Treat. 2020. https://doi.org/10.4143/crt.2020.330.

20. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-2646. https://doi.org/10.1016/S0140-6736(19)31138-9.

21. Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition (Edinburgh, Scotland). 2019;38(1):1-9. https://doi.org/10.1016/j.clnu.2018.08.002.

22. Makriu D, Ono R, Inoue J, et al. Impact of sarcopenia on unplanned readmission and survival after esophagectomy in patients with esophageal cancer. Ann Surg Oncol. 2018;25(2):456-464. https://doi.org/10.1245/s10434-017-6294-4.
23. Hopkins JJ, Reif RL, Bigam DL, Baracos VE, Eurich DT, Sawyer MB. The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer. *Dis Colon Rectum*. 2019;62(5):549-560. https://doi.org/10.1097/DCR.0000000000001352.

24. Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. *Br J Surg*. 2013;100(11):1523-1530. https://doi.org/10.1002/bjs.9258.

25. Deng L, Wang Y, Zhao J, et al. The prognostic value of sarcopenia combined with hepatolithiasis in intrahepatic cholangiocarcinoma patients after surgery: a prospective cohort study. *Eur J Surg Oncol*. 2021;47(3 Pt B):603-612. https://doi.org/10.1016/j.ejso.2020.09.002.

26. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48(1):16-31. https://doi.org/10.1093/ageing/afy169.

27. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95-101. https://doi.org/10.1016/j.jamda.2013.11.025.

28. Golse N, Bacur PO, Ciacio O, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. *Liver Transpl*. 2017;23(2):143-154. https://doi.org/10.1002/lt.24671.

29. Masuda T, Shirabe K, Ikegami T, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. *Liver Transpl*. 2014;20(4):401-407. https://doi.org/10.1002/lt.23811.

30. Lu LH, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study. *Liver International*. 2020. https://doi.org/10.1111/liv.14567.

31. Miyata T, Yamashita YI, Higashi T, et al. The prognostic impact of controlling nutritional status (CONUT) in intrahepatic cholangiocarcinoma following curative hepatectomy: a retrospective single institution study. *World J Surg*. 2018;42(4):1085-1091. https://doi.org/10.1007/s00268-017-4214-1.

32. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nat Rev Cancer*. 2013;13(11):759-771. https://doi.org/10.1038/nrc3611.

33. Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma. *Ann Surg Oncol*. 2017;24(5):1351-1357. https://doi.org/10.1245/s10434-016-5708-z.

34. Wu Y, Ren F, Chai Y, et al. Prognostic value of inflammation-based indexes for intrahepatic cholangiocarcinoma following curative resection. *Oncol Lett*. 2019;17(1):165-174. https://doi.org/10.3892/ol.2018.9618.

35. Jansson H, Cornillet M, Bjorkstrom NK, Sturesson C, Sparrelid E. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer – Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. *Eur J Surg Oncol*. 2020;46(5):804-810. https://doi.org/10.1016/j.ejso.2019.12.008.

36. An Q, Liu W, Yang Y, Yang B. Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IB-IIA cervical cancer. *BMC Cancer*. 2020;20(1):691. https://doi.org/10.1186/s12885-020-07191-8.

37. Tang S, Lin L, Cheng J, et al. The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer. *BMC Cancer*. 2020;20(1):382. https://doi.org/10.1186/s12885-020-06866-6.

38. Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. *J Cachexia Sarcopenia Muscle*. 2017;8(1):113-121. https://doi.org/10.1002/jcsm.12095.

39. Hahn F, Muller L, Stohr F, et al. The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: prognostic marker or hyped parameter? *Liver Int*. 2019;39(7):1307-1314. https://doi.org/10.1111/liv.14132.

40. Chakedis J, Spolverato G, Beal EW, et al. Pre-operative sarcopenia identifies patients at risk for poor survival after resection of biliary tract cancers. *J Gastrointest Surg*. 2018;22(10):1697-1708. https://doi.org/10.1007/s11605-018-3802-1.

41. Okumura S, Kaido T, Hamaguchi Y, et al. Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholangiocarcinoma. *Ann Surg Oncol*. 2017;24(4):1037-1045. https://doi.org/10.1245/s10434-016-5668-3.

**How to cite this article:** Yu H, Wang M, Wang Y, et al. The prognostic value of sarcopenia combined with preoperative fibrinogen–albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study. *Cancer Med*. 2021;00:1–13. https://doi.org/10.1002/cam4.4035